Filtered By:
Condition: Hypertension
Cancer: Adenocarcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 168 results found since Jan 2013.
The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
CONCLUSIONS: This is the first report to our knowledge of a patient who presented with gastric and hepatic metastases from lung cancer and achieved complete remission with osimertinib and local radiotherapy, with good quality of life, which also provides a basis for future clinical work and is of great significance.PMID:37695388 | DOI:10.1007/s00432-023-05386-7
Source: Clinical Lung Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Yun Wang Chao Yan Chuantao Zhang Enhao Yu Kai Wang Xiangyong Liu Jie Yu Chunyang Zhou Aijie Yang Source Type: research
Infliximab for vascular involvement in Beh çet's syndrome
CONCLUSION: Infliximab seems to be effective in majority of BS patients with vascular involvement, even in those who are refractory to immunosuppressives and glucocorticoids.PMID:37385325 | DOI:10.1016/j.clim.2023.109682
Source: Clinical Immunology - June 29, 2023 Category: Allergy & Immunology Authors: Gulen Hatemi Nur Beyza Tukek Sinem Nihal Esatoglu Yesim Ozguler Sitki Safa Taflan Ugur Uygunoglu Melike Melikoglu Serdal Ugurlu Izzet Fresko Aksel Siva Zekayi Kutlubay Sebahattin Yurdakul Hasan Yazici Vedat Hamuryudan Source Type: research
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
Clin Cancer Res. 2023 Jun 2:OF1-OF6. doi: 10.1158/1078-0432.CCR-23-0459. Online ahead of print.ABSTRACTOn September 21, 2022, the FDA granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The approval was based on data from Study LOXO-RET-17001 (LIBRETTO-001; NCT03157128), an international, non-randomized, multi-cohort clinical trial that in...
Source: Clinical Breast Cancer - June 2, 2023 Category: Cancer & Oncology Authors: Elizabeth S Duke Diana Bradford Michelle Marcovitz Anup K Amatya Pallavi S Mishra-Kalyani Emily Nguyen Lauren S L Price Jeanne Fourie Zirkelbach Yangbing Li Youwei Bi Jeffrey Kraft Sarah E Dorff Barbara Scepura Maritsa Stephenson Idara Ojofeitimi Abhilash Source Type: research
